Bruce Keyt

Company: IGM Biosciences

Job title: Chief Scientific Officer

Seminars:

Revolutionizing Bispecific Drugs for Autoimmune & Inflammatory Diseases Treatment of Autoantibody-Driven Diseases with Bispecific T Cell Engaging IgM Antibodies 10:30 am

Highlighting the unique potential of IgM antibodies for treatment of autoimmune disease Utilizing T cells to drive deep B cell depletion for B cell mediated autoimmune diseases Sharing pipeline updates including the ongoing imvotamab (CD20 x CD3) Phase 1b clinical trialsRead more

day: Day Two